An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

• Proportion of patients achieving ≥50% reduction in OCS dose [ Time Frame: Week 0 through study week 24 ]
• Proportion of patients achieving OCS dose reduction to ≤5mg daily dose [ Time Frame: Week 0 through study week 24 ]
• Percent change from baseline in OCS dose [ Time Frame: Week 0 through study week 24 ]
• Proportion of patients achieving less than 5 mg decrement in OCS dose compared to the baseline OCS dose [ Time Frame: Week 0 through study week 24 ]
• Annualized rate of clinical asthma exacerbations [ Time Frame: Week 0 through study week 24 ]
  Annualized rate of clinical asthma exacerbations requiring a burst of systemic corticosteroid (injection, or if oral, at least a doubling from the current OCS dose for at least 3 days); an asthma-specific hospital admission; or an asthma-specific emergency department visit
• Proportion of patients discontinuing OCS [ Time Frame: Week 0 through study week 24 ]
• Time to first clinical asthma exacerbation [ Time Frame: Week 0 through study week 24 ]
• Pre-bronchodilator FEV1: change from baseline [ Time Frame: Week 0 through study week 24 ]
• Post-bronchodilator FEV1: change from baseline [ Time Frame: Week 0 through study week 24 ]
• Ambulatory lung function: change in peak expiratory flow (PEF) from run-in baseline [ Time Frame: Week 0 through study week 24 ]
• Asthma Quality of Life (AQLQ) + 12 score: change from baseline [ Time Frame: Week 0 through study week 24 ]
• ACQ-6: change from baseline [ Time Frame: Week 0 through study week 24 ]
• Change in nighttime awakenings due to asthma requiring rescue inhaler from run-in baseline [ Time Frame: Week 0 through study week 24 ]
• Change in total asthma symptom scores from run-in baseline [ Time Frame: Week 0 through study week 24 ]
• European Quality of Life 5-dimension health state utility index (EQ-5D) score: change from baseline [ Time Frame: Week 0 through study week 24 ]
• St. George's Respiratory Questionnaire (SGRQ) score: change from baseline [ Time Frame: Week 0 through study week 24 ]
• Change in total rescue inhaler use from run-in baseline [ Time Frame: Week 0 through study week 24 ]
• Serum response relationships [ Time Frame: Week 0 through study week 24 ]
  Serum reslizumab concentrations to characterize PK and assess exposure response relationships
• Immunogenicity as assessed by anti-drug antibodies (ADA) [ Time Frame: Week 0 through study week 48 ]
• Percentage of participants with adverse events [ Time Frame: Week 0 through study week 32 ]

• Asthma
• Elevated Blood Eosinophils

• Drug: Reslizumab
  Reslizumab Subcutaneous Dosing
• Drug: Placebo

• Experimental: Reslizumab
  Reslizumab Subcutaneous Dosing
  Intervention: Drug: Reslizumab
• Placebo Comparator: Placebo
  Matching placebo
  Intervention: Drug: Placebo

Inclusion Criteria:

1. The patient is male or female, 12 years of age and older, with a previous diagnosis of asthma.
2. Written informed consent is obtained.
3. The patient requires daily maintenance dose of prednisone or equivalent for asthma of between 5 and 40 mg during the 3 months prior to screening.
4. The patient has a documented elevated blood eosinophils at screening or during the previous 12 months.
5. The patient has required high dose ICS plus another asthma controller for at least 6 months prior to screening.

6. The patient has FEV1 reversibility to inhaled SABA or historical reversibility within the previous 24 months.

   • Other criteria may apply, please contact the investigator for more information.

Exclusion Criteria:

1. The patient has any clinically significant, uncontrolled medical condition that would interfere with the study schedule or procedures and interpretation of efficacy results or would compromise the patient's safety.
2. The patient has another confounding underlying lung disorder.
3. The patient has a known hypereosinophilic syndrome.
4. The patient has a history of any malignancy within 5 years of the screening visit, except for treated and cured non-melanoma skin cancers.
5. The patient is pregnant or intends to become pregnant during the study or is lactating.
6. The patient required treatment for an asthma exacerbation within 4 weeks of screening.
7. The patient is a current smoker or has a smoking history ≥10 pack-years.
8. The patient is currently using any systemic immunosuppressive or immunomodulatory biologic except maintenance OCS for the treatment of asthma.
9. The patient participated in a clinical study within 30 days or 5 half-lives of the investigational drug before screening, whichever is longer.
10. The patient was previously exposed to benralizumab within 12 months of screening.
11. The patient was previously exposed to reslizumab.
12. The patient has a history of immunodeficiency disorder including human immunodeficiency virus.
13. The patient has current suspected drug and/or alcohol abuse.
14. The patient has had an active helminthic parasitic infection or was treated for one within 6 months of screening.

15. The patient has a history of allergic reactions or hypersensitivity to any component of the study drug.

    • Other criteria may apply, please contact the investigator for more information.